Glenmark Pharmaceuticals today said the US health regulator has granted tentative approval for tablets used for treatment of overactive bladder.
“We have been granted tentative approval by the United States Food and Drug Administration (USFDA) for Solifenacin Succinate tablets-5 mg and 10 mg,” Glenmark Pharmaceuticals said in a BSE filing.
The company’s products are the generic version of Vesicare tablets, 5 mg and 10 mg of Astellas Pharma US Inc.
According to IMS Health April 2017 sales data, the market for Vesicare tablets-5 mg and 10 mg, saw annual sales of approximately $ 1.1 billion.
Glenmark’s current portfolio consists of 117 products authorised for distribution in the US marketplace, the company said, adding that it has 68 Abbreviated New Drug Applications (ANDA) pending with the USFDA.
The scrip was trading 0.79 per cent higher at Rs 633.65 on the BSE.